報價延遲最少15分鐘:2025/06/02 18:41 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.06 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.39/-0.68
|
|
企業價值
62.00M
|
| 資產負債 |
|
每股賬面淨值
0.41
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/02 18:41 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential. |